LGX 818 (Encorafenib)

Catalog No. A13226

LGX 818 (Encorafenib)是一种Raf激酶抑制剂，具有潜在的抗肿瘤活性。

Product Citations

Seidel D, .et al. A multidimensional impedance platform for the real-time analysis of single and combination drug pharmacology in patient-derived viable melanoma models, Biosens Bioelectron, 2019, Jan 1;123:185-194 PMID: 30201332

Technical details

Catalog Num	A13226
M. Wt	540.01
Formula	C22H27ClFN7O4S
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	1269440-17-6, 1269440-29-0
Synonyms	LGX818, LGX-818
SMILES	C[C@@H](CNC1=NC=CC(=N1)C2=CN(N=C2C3=CC(=CC(=C3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC

Biological Activity

LGX 818 (Encorafenib)是一种Raf激酶抑制剂，具有潜在的抗肿瘤活性。

Targets

B-Raf (V600E)
4 nM(EC50)

Solubility *

In vitro	DMSO	93 mg/mL (172.22 mM)
	Water	Insoluble
	Ethanol	93 mg/mL (172.22 mM)
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	18.52 mL	92.59 mL	185.18 mL
0.5 mM	3.7 mL	18.52 mL	37.04 mL
1 mM	1.85 mL	9.26 mL	18.52 mL
5 mM	0.37 mL	1.85 mL	3.7 mL

*The above data is based on the productmolecular weight 540.01. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.